Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points.

Of the five newcos, HiberCell Inc. (New York, N.Y.) raised the largest venture round, bringing in $60.8 million in a series A round led by Arch Venture Partners. The company, which is developing therapies that prevent cancer relapse and metastasis, is led by former Warp Drive Bio Inc. executives Alan Rigby and Mark Mulvihill (see “HiberCell Launches with over $60M to Target Dormant Cancer Cells”)...